Recently, large-scale observational studies are becoming increasingly important as complementary tools for randomized control trials, several non-interventional studies have evaluated the effectiveness and safety of bevacizumab plus paclitaxel for HER2-negative advanced breast cancer patients in the real world [9]. The gene discussed is ERBB2; the disease is breast carcinoma.